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performed. JCPyV efficiently replicated in kidney-derived 
COS-7 cells, as demonstrated by a progressive increase in 
viral load and virion particle production after transfection. 
The archetypal structure of NCCR was maintained during 
the viral cycle, but two characteristic point mutations were 
detected 28 days after transfection. This model is a useful 
tool for analyzing NCCR rearrangements during in vitro 
replication in cells that are sites of viral persistence, such as 
tubular epithelial cells of the kidney.
Introduction
John Cunningham virus (JCPyV) is a member of the family 
Polyomaviridae, and it has a small circular double-stranded 
DNA genome. JCPyV was isolated in 1971 from the brain 
of a patient with Hodgkin’s disease, and it is the etiological 
agent of the progressive multifocal leukoencephalopathy 
(PML), a demyelinating disease of the brain [1].
The JCPyV genome contains two protein-coding regions 
(early and late), which are transcribed in opposite direc-
tions starting from a common non-coding control region 
(NCCR), the most variable portion of the viral genome. 
The NCCR contains promoter/enhancer elements and the 
origin of viral DNA replication [2].
The early region encodes the regulatory proteins large 
T antigen (TAg) and small t antigen (tAg). During early 
phase, TAg accumulates and directs initiation of viral DNA 
replication and the transcriptional switch from early to late 
gene expression at the onset of the late phase [3]. The late 
region encodes the viral capsid proteins VP1, VP2, and 
VP3 and a small regulatory protein, agnoprotein, which is 
an important factor in the regulation of the viral life cycle. 
Finally, a gene encoding microRNAs has been identified in 
the distal part of TAg gene [4].
Abstract John Cunningham virus (JCPyV) is an ubiqui-
tous human pathogen that causes disease in immunocom-
promised patients. The JCPyV genome is composed of an 
early region and a late region, which are physically sepa-
rated by the non-coding control region (NCCR). The DNA 
sequence of the NCCR distinguishes two forms of JCPyV, 
the designated archetype and the prototype, which resulted 
from a rearrangement of the archetype sequence. To date, 
the cell culture systems for propagating JCPyV archetype 
have been very limited in their availability and robust-
ness. Prior to this study, it was demonstrated that JCPyV 
archetype DNA replicates in COS-7 simian kidney cells 
expressing SV40 TAg and COS-7 cells expressing HIV-1 
Tat. Based on these observations, the present study was 
conducted to reproduce an in vitro model in COS-7 cells 
transfected with the JCPyV archetype strain in order to 
study JCPyV DNA replication and analyze NCCR rear-
rangements during the viral life cycle. The efficiency of 
JCPyV replication was evaluated by quantitative PCR 
(Q-PCR) and by hemagglutination (HA) assay after trans-
fection. In parallel, sequence analysis of JCPyV NCCR was 
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The archetype NCCR (CY strain) is divided into six 
regions, named box A (36 bp), box B (23 bp), box C (55 
bp), box D (66 bp), box E (18 bp), and box F (69 bp) [5]. 
Each region contains binding sites for host transcription 
factors involved in viral early and late transcription. These 
binding sites undergo deletion and enhancement processes 
that generate variants that can upregulate viral expression 
at specific anatomical sites [6, 7]. JCPyV with the arche-
type sequence, which is found in the kidney and urine, is 
not associated with PML and is not infectious in tissue cul-
ture models. Prototype NCCRs are variants isolated from 
tissues of patients with PML, and they are named based on 
the hypothesis that the prototypes result from a rearrange-
ment of the archetype sequence [8]. The original prototype 
is the Mad-1 isolate, which contains a 98-bp tandem repeat 
(A-C-E-A-C-E-F) [2, 9].
PML was originally recognized as a rare complication 
of hematological malignancies or systemic inflammatory 
disorders; however, a dramatic 50-fold increase in the inci-
dence occurred with the human immunodeficiency virus 
(HIV) epidemic. Moreover, PML can be seen after organ 
and stem cell transplantation and, recently, in patients 
under treatment with immunomodulatory compounds such 
as monoclonal antibodies (mAbs) [10–12].
Infection with JCPyV is widespread in the general popu-
lation, with more than 80% being seropositive by adulthood 
[13]. Nevertheless, the mode of transmission is not yet well 
defined, although the presence of JCPyV DNA in B cells 
and stromal cells of the tonsils and oropharynx supports 
the proposal that tonsils may serve as an initial site of viral 
infection [14]. Virus might enter the mouth or nose through 
close interpersonal contact or via fomites, and it presum-
ably spreads by the hematogenous route from the primary 
site of infection to secondary sites such as kidneys, lym-
phoid tissues, and brain to establish focal areas of infection 
or persistence [15–17].
JCPyV is a neurotropic virus; nevertheless, it is still 
incompletely understood how the virus infects the central 
nervous system (CNS). There are two possibilities: JCPyV 
infects the CNS in cases where the immune response is 
altered; alternatively, the virus infects the CNS and persists 
there for many years. When alteration of the immune sys-
tem occurs, viral infection emerges [12].
Although rearrangement of the NCCR of archetype 
JCPyV is thought to be an important event in the patho-
genesis of PML, little is known regarding what induces 
this rearrangement [18]. It is not yet understood where 
these rearrangements take place, if they occur in latent cells 
(bone marrow, precursors of hematopoietic  CD34+ cells, B 
cells) or in the brain, during primary or persistent infection. 
Although various amounts of JCPyV DNA can be found 
in different blood cell types, there is no direct evidence of 
productive infection or the presence of viral RNA, proteins 
or virions [19].
The host cell range of archetype JCPyV is very restricted 
in cultured cells. Although human primary oligodendro-
cytes would be the most pathophysiologically relevant in 
vitro model for PML, these cells are difficult to obtain and 
propagate. Previous reports have demonstrated that arche-
type JCPyV replicates efficiently in simian-kidney-derived 
COS-7 cells expressing simian virus 40 (SV40) T antigen 
and in COS-7 cells expressing HIV-1 Tat [20, 21]. It is also 
important to know that other JCPyV strains, such as Mad-4, 
replicate efficiently in simian-kidney-derived COS-7 cells 
[22], and other cell lines, such as the human embryonic 
kidney (HEK) cell line 293TT [23] and the human fetal 
glial cell line SVG, have been employed to study the virus 
[24]. Although clearly different from primary oligodendro-
cytes, these cell lines support rapid replication of JCPyV.
The focus of our research was to validate an in vitro 
model in simian-kidney-derived COS-7 cells to study the 
growth characteristics of JCPyV and to analyze possible 
NCCR rearrangements that occur after transfection.
Materials and methods
Cell line
COS-7 cells were obtained from the ATTC (ATCC® 
CRL-1651™). COS-7 is a derivative of CV-1(ATCC® 
CCL-70™), a cell line established from the kidney of an 
African green monkey that was transformed with an origin-
defective mutant of SV40 [25]. Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 100 U of penicil-
lin, 100 μl of streptomycin per ml, (Sigma-Aldrich S.r.l., 
Milano, Italia) and fetal bovine serum (FBS) (10%) was 
used as maintenance medium for the cell line. The cells 
were incubated at 37 °C in the presence of 5%  CO2 and 
propagated at a ratio of 1:4 or 1:8.
Transformation of competent bacteria
The pCY/cl1 plasmid, which carries the archetype JC 
genome sequence, was purchased from ATCC (ATCC® 
VRMC-1™). The JCPyV DNA was recovered for BamHI-
digested pCY/cl1 plasmid and the JC linear DNA was 
gel-extracted and purified using a GenepHlow ™ DNA 
Cleanup Maxi Kit (Geneaid Biotech Ltd., New Taipei City, 
Taiwan). The DNA was quantified, and 1 μg was used for 
transfection experiments.
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Transfection
COS-7 cells were plated with a density of 7.5 ×104 and 
grown for 24 h in complete growth medium in order to reach 
50-70% confluence on the day of transfection. The cells were 
then transfected with 1 µg of JCPyV CY strain DNA follow-
ing the specifications of the Xfect ™ Transfection Reagent 
kit (Clontech Laboratories, Inc., Mountain View, CA, USA). 
The cells were incubated at 37 °C for 4 hours with the trans-
fection mixture. After two washes with phosphate-buffered 
saline (PBS), the cells were incubated with complete culture 
medium for the time course experiment. After two days of 
incubation, the cells were transferred to a 34-ml flask and 
then continuously cultured in the maintenance medium with 
transfer at a split ratio of 1:3/1:4 every 3 or 4 days. Super-
natant and cellular fractions were harvested and stored two 
times a week until 35 days post-transfection (p.t.).
Extraction of viral DNA from COS‑7 cells and from 
supernatants
The total DNA was extracted from 1 ×  106 COS-7 cells 
using a QIAmp® DNA Mini Kit (QIAGEN S.p.A., Milan, 
Italy), following the instructions provided by the manufac-
turer. Once extracted, the DNA was stored at -20 °C until 
use.
The culture medium from COS-7 cells was initially sub-
jected to six cycles of freezing and thawing and then centri-
fuged at 2000 rpm for 10 minutes, and the resulting super-
natant was used directly in molecular biology assays.
Hemagglutination (HA) assay
As JCPyV capsids have the property of agglutinating 
human type O erythrocytes and the HA assay has tradi-
tionally been used to determine virus titer [21], the cells 
were subjected to freeze-thaw cycles. The cell lysates 
were treated with 50 μg of neuraminidase (Type V; Sigma-
Aldrich) per ml at 37 °C overnight, incubated at 56 °C for 
30 min, and centrifuged at 200 × g for 10 min at 4 °C. The 
supernatant was serially diluted with 50 μl of PBS in a 
96-well round microplate (Costar, Cambridge, MA, USA). 
The sample was mixed with 50 μl of 0.5% human type 
O erythrocytes and was further incubated for 3 h at 4 °C. 
The HA titer was defined as the reciprocal of the highest 
dilution of virus suspension at which complete HA was 
observed. The HA activity at the endpoint dilution was 
considered 1 hemagglutination unit (HAU).
Quantitative PCR (Q‑PCR)
Extracted DNA was analyzed using Q-PCR for the detec-
tion and quantification of the JCPyV genome using a 7300 
Real-Time PCR System (Applied Biosystems, USA), follow-
ing a published protocol [26]. Each sample was analyzed in 
triplicate, and the viral loads were given as the mean of at least 
three positive reactions. Standard precautions designed to pre-
vent contamination were followed, and a negative control was 
included in each run. Viral DNA was quantified using a stand-
ard curve consisting of serial dilutions of a plasmid containing 
the entire JCPyV genome with a known titer (range,  105 gEq/
ml–102 gEq/ml). The amount of cellular DNA was quantified 
simultaneously using a SYBR GREEN PCR for the house-
keeping β-globin gene [27] and used to normalize the JCPyV 
DNA. The data were expressed as genome equivalents (gEq) 
of viral DNA per cell based on DNA content (gEq/cell) for the 
COS-7 cells and as genome equivalents (gEq) of viral DNA 
per milliliter (gEq/ml) for the supernatants.
PCR for JCPyV NCCR
The JCpyV NCCR genomic sequence was amplified using 
two primers that flank two invariant regions [6]. The prim-
ers generated a fragment of 308 bp [28, 29]. Standard pre-
cautions were adopted in order to prevent contamination, 
and a negative control was included in each set of experi-
ments [30]. PCR products were detected by electrophoresis 
on an ethidium-bromide-stained 2% agarose gel and visual-
ized under UV light.
Sequencing of the JCPyV NCCR
PCR products corresponding to the JCPyV NCCR region 
were purified prior to sequencing [6]. DNA sequencing was 
performed by a professional service (BioFab research s.r.l., 
Rome, Italy). All sequences obtained from NCCR amplicons 
were compared to the NCCR of the JCPyV prototype Mad-1 
(GenBank: J02227) and to that of the archetype CY (Gen-
Bank: AB038249.1). Sequence alignments were performed 
with Clustal W2 at the EMBL-EBI website using default 
parameters (ClustalW2-multiple sequence alignment 1) [31].
Data analysis
Data were expressed as the median and range or as the 
mean ± standard deviation, as appropriate. Data were ana-
lyzed by Student’s t-test. P < 0.05 was considered statisti-
cally significant.
Results
Replication efficiency of JCPyV CY in COS‑7 cells
In order to evaluate the efficiency of JCPyV replication, 
COS-7 cells were transfected with 1 µg of DNA of the 
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JCPyV CY archetype strain using an Xfect™ Transfection 
Reagent kit (Clontech Laboratories, Inc., Mountain View, 
CA, USA). The transfected cells were grown in mainte-
nance medium for the time course experiment and serially 
transferred at a split ratio of 1:3 or 1:4 every 3 or 4 days. 
On day 14, a rounding of the cells started to appear in the 
cells transfected with the JCPyV CY archetype strain.
Two times a week until day 35 p.t., cells and superna-
tants were harvested. Samples taken 2 days (T2) after trans-
fection (T0) represented input DNA. In total, the samples 
were collected at 4 (T4), 7 (T7), 11 (T11), 14 (T14), 18 
(T18), 21 (T21), 25 (T25), 28 (T28) and 35 (T35) days p.t.
Intracellular viral DNA was extracted from 1 ×  106 
COS-7 cells after transfection at the selected sampling time 
(T2-T35) and used in a quantitative PCR (Q-PCR) assay 
for JCV TAg in order to evaluate the efficiency of JCPyV 
replication.
Results of Q-PCR obtained from three independent exper-
iments revealed that JCPyV efficiently replicated in COS-7 
cells. In fact, the average JCPyV viral load at T2 was 1.50 
×  102 gEq/cell. A decrease in viral replication was observed 
during the first 18 days p.t. with a progressive increase at 
T21 (4.49 ×  103 gEq/cell), T25 (7.82 ×  104 gEq/cell), T28 
(3.19 ×  105 gEq/cell) and T35, when the JCPyV viral load 
reached the maximum value of 6.66 ×  105 gEq/cell (Fig. 1).
In parallel, JCPyV replication was also evaluated by 
measuring viral DNA in the supernatants, which were 
harvested at the same cell sampling times (T2-T35) and 
subjected to six cycles of freezing and thawing before 
being assayed by Q-PCR. At two days p.t. (T2), the cul-
ture medium showed a JCPyV load average of 3.68 × 
 104 gEq/ml. The trend of the JCPyV load in the superna-
tant was essentially the same as that observed in the cells, 
with a decrease of viral replication in the first 14 days p.t. 
(Fig. 1). The amount of viral DNA progressively increased 
for 18 days (T18) (3.38 ×  105 gEq/ml), reaching a maxi-
mum at 35 days p.t. (T35), with an average value of 7.07 × 
 107 gEq/ml (Fig. 1).
Comparing the intracellular JCPyV DNA loads (gEq/
cell) with those found in the supernatants (gEq/ml), it was 
observed that JCPyV replication showed the same trend dur-
ing the sampling period (T2-T35). The efficiency of JCPyV 
replication during the time course experiment was also 
estimated by hemagglutination (HA) assay, which is tradi-
tionally employed for quantitation of JCPyV. The JCPyV 
major capsid protein, VP-1, is responsible for red blood cell 
(RBC) agglutination. The supernatants that were utilized 
for Q-PCR were assayed for hemagglutination (HA), with 
the results expressed as a titer. The data showed that the HA 
titer changed with time. In the archetype-transfected cul-
tures, HA began to be detected on day 14 (T14) (HA = 2) 
and reached the highest titer on day 35 (T35) (HA = 128).
The HA titer and Q-PCR values progressively increased 
during the course of transfection, although a quantitative 
discrepancy between the HA titer and the Q-PCR data 
was found: the HA titers were low until 14 days p.t. (T14) 
despite the presence of an average viral load detected by 
the real-time assays. From T18 to T35, the HA titer and 
Q-PCR values progressively increased (Fig. 2).
Sequence analysis of JCPyV NCCR in cells 
and supernatants at various sampling times
In order to evaluate whether the JCPyV CY archetype 
strain undergoes rearrangements after being introduced 
into the permissive cell line COS-7, sequence analysis of 
the NCCR was performed.
Viral DNA extracted from COS-7 cells and superna-
tants, harvested at various sampling times post-transfec-
tion (T2-T35), was used in a PCR employing two pairs 
of primers that anneal to the invariant regions flanking 
JCV NCCR. PCR products were purified and sequenced 
as described in Materials and methods.
Within cell and supernatant samples, the sequence 
analysis of JCV NCCR showed an archetype-CY-like 
structural organization during viral growth in COS-7 
cells until 25 days post-transfection (T25), with the pres-
ence of box A (36 bp), box B (23 bp), box C (55 bp), 
box D (66 bp), box E (18 bp) and box F (69 bp) (Fig. 3).
Fig. 1  Replication efficiency of JCPyV CY in COS-7 cells and in 
supernatants. The efficiency of JCPyV replication was assessed at 
selected sampling times after transfection from 48 hours (T2) p.t. 
until 35 days (T35). JCPyV DNA was quantified by Q-PCR. The 
increase in JCPyV replication in COS-7 cells (squares) and in the 
supernatant (diamonds) during the transfection experiments is shown. 
Data are expressed as the mean of three independent experiments, 
and error bars indicate standard deviations. gEq/cell, genome equiva-
lents of viral DNA per cell in COS-7 cells; gEq/ml, genome equiva-
lents of viral DNA per milliliter in the supernatants. T2, 2 days p.t.; 
T4, 4 days p.t.; T7, 7 days p.t.; T11, 11 days p.t.; T14, 14 days p.t; 
T18. 18 days p.t.; T21, 21 days p.t.; T25, 25 days p.t.; T28, 28 days 
p.t.; T35, 35 days p.t
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Consequently, binding sites for some cell factors 
involved in viral transcription, such as Tst-1 in box A, 
Sp1 in box B and NF-1, CRE, and up-TAR in box C, 
were maintained (Fig. 3). Finally, five or six point muta-
tions were found in the different sequenced samples, but 
they did not involve known binding sites for transcrip-
tion factors (data not shown).
The analysis of cell and supernatant samples from 
T28 and T35 revealed an archetype-CY-like NCCR with 
two characteristic point mutations: the 37T-to-G nucleo-
tide transversion within the binding site for the cellular 
transcription factor Spi-B in box B and the 217G-to-A 
nucleotide transition in box F at the level of the binding 
site for the cellular transcription factor NF-1 (Fig. 3).
Discussion
The natural course of JCPyV infection is life-long per-
sistence in the case of immunocompetent hosts, but the 
mechanism by which JCPyV establishes this delicate equi-
librium within the host remains poorly defined. JCPyV 
infection is very common and sero-epidemiological studies 
have shown that initial infection occurs early in life [13]. 
In fact, archetype JCPyV (CY strain) infects children and 
establishes asymptomatic and persistent infection in the 
kidneys, with occasional shedding in urine when low-level 
replication of persistent virus occurs in tubular epithelial 
cells [19]. Specific T-cell immunity plays a significant role 
in controlling JCPyV replication and protection from PML 
[32]. Archetype JCPyV has also been detected repeatedly 
in human peripheral blood mononuclear cells (PBMCs) – 
more specifically, B cells – and it is possible that the virus 
establishes a subclinical infection in other immune cells, 
such as bone marrow progenitor cells [33, 34]. The rear-
ranged form of JCPyV (prototype NCCR, also known as 
PML-type JCV) can be isolated from the brain and lym-
phocytes in people with and without PML and is typified 
by the Mad-1 strain of JCPyV [8, 17, 24]. The prototype 
variant has high replication capacity and has been associ-
ated with insufficient or dysregulated T-cell responses [32].
To date, cell culture systems to propagate JCPyV have 
been very limited in their availability and robustness. Based 
on this observation, our aim was to produce a model to 
study the growth characteristics of JCPyV and to analyze 
the possible NCCR rearrangements that occurred after 
transfection. The large amount of JCPyV DNA detected 
during the time course of transfection confirms the abil-
ity of JCPyV to replicate in simian-kidney-derived COS-7 
cells expressing SV40 TAg. The levels of JCPyV replica-
tion showed the same trend in the cells and supernatants, 
but the amount of viral DNA found in the supernatants was 
higher than in the cellular fraction. This is due to an effi-
cient release of free virions in the culture medium. Moreo-
ver, the detachment of infected cells from the surface of the 
flasks due to the intensive utilization of cellular resources 
by JCPyV for its life cycle contributes to the massive pres-
ence of viral DNA in the supernatant. Although, it had been 
demonstrated prior to this study that archetype JCPyV 
DNA replicates in COS-7 simian kidney cells express-
ing SV40 TAg and COS-7 cells expressing HIV-1 Tat [20, 
21], the novelty of our work is that we monitored JCPyV 
Fig. 2  Analysis of HA and Q-PCR data employed for JCPyV quan-
tification. The data represent two independent experiments compar-
ing Q-PCR and the HA assay for the in vitro quantification of JCPyV. 
Samples were tested in triplicate for each run of Q-PCR. Error bars 
indicate standard deviations. gEq/ml, genome equivalents of viral 
DNA per milliliter in the supernatants; HA, HA titer; T2, 2 days p.t.; 
T4, 4 days p.t.; T7, 7 days p.t.; T11, 11 days p.t.; T14, 14 days p.t; 
T18. 18 days p.t.; T21, 21 days p.t.; T25, 25 days p.t.; T28, 28 days 
p.t.; T35, 35 days p.t
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replication more precisely by Q-PCR during transfection. 
As described in the results, the HA titer, which is tradition-
ally used to determine virus titer, and Q-PCR values pro-
gressively showed the same trend of increase during the 
course of transfection, although a quantitative discrepancy 
between the HA titer and Q-PCR data was found, with HA 
titers remaining low until 14 days p.t. (T14) despite the 
presence of an average viral load detected by Q-PCR. From 
T18 to T35, HA titer and Q-PCR values progressively 
increased. Q-PCR is a more sensitive and reliable method 
for in vitro quantification. As described by Chapagain and 
colleagues [35], Q-PCR has proven to be an important 
method for monitoring JCPyV viral load in clinical speci-
mens, and it is a reliable marker for PML prognosis.
The second novel aspect of our work is that we studied 
the molecular characteristics of the JCPyV NCCR after 
transfection in an effort to determine whether the archetype 
strain undergoes rearrangements in the permissive COS-7 
cells. The mechanisms that induce rearrangements in the 
NCCR are still poorly understood. Our results showed that 
an archetype CY-like structural organization of the NCCR 
was consistently maintained, with the presence of all bind-
ing sites for cellular factors involved in viral transcription 
in all samples (cells and supernatants) collected from the 
input JCPyV DNA until 25 days p.t. It should be noted that 
the archetypal structure of the NCCR was maintained dur-
ing viral growth, although the archetype generates various 
PML-type regulatory regions by deletion and amplifica-
tion during persistence of JCV in patients [5, 20, 36–40]. 
This could be due to the fact that the transfected cells were 
grown for a few weeks, a period much shorter than that of 
the persistence of the CY strain in humans [20]. Surpris-
ingly starting from 28 days post-transfection, analysis of 
the NCCR revealed an archetype-CY-like structural organi-
zation with two characteristic point mutations: the 37T-to-G 
nucleotide transversion within the binding site for the cel-
lular transcription factor Spi-B in box B and the 217G-to-A 
nucleotide transition in box F at the level of the binding site 
for the cellular transcription factor NF-1. For the first time, 
these point mutations were detected in an NCCR structure 
derived from an in vitro replication. They were previously 
reported in urine of immunocompetent individuals [41] and 
Fig. 3  Sequences of the NCCR 
of JCPyV found in samples 
of cells and supernatants from 
renal cell line COS-7 at various 
sampling times post-tranfection. 
An alignment is shown between 
the nucleotide sequence of the 
archetype NCCR (CY strain), 
isolated by Yogo and colleagues 
in 1990 [5], and that obtained 
from the sequencing of viral 
DNA extracted from COS-7 
cells and from supernatants 
after transfection. The NCCR of 
the JCPyV CY strain is gener-
ally divided into six regions, 
named box (A [25 bp], B [23 
bp], C [55 bp], D [66 bp], E 
[18 bp] and F [69 bp]), which 
are shown below the sequence 
alignment. The 37 T-to-G 
nucleotide transversion within 
the binding site for the cellular 
transcription factor Spi-B in 
box B and the 217 G-to-A 
nucleotide transition in box F at 
the level of the binding site for 
the cellular transcription factor 
NF-1 are shown
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in urine and PBMCs of multiple sclerosis patients under-
going natalizumab treatment [42]. It should be noted that 
the 37T-to-G nucleotide transversion in box B is located 
within the binding site for the cellular transcription factor 
Spi-B, which can play a crucial role in viral replication and 
neurovirulence. It is known that Spi-B carries out two func-
tions in JCPyV replication. The first one is the activation of 
the JCPyV early promoter in both glial and non-glial cells 
in relation to its binding to box B site, and the second one 
is the TAg-mediated transactivation of viral early genes in 
relation to its binding to the site located in box D [7, 43]. 
Regarding the 217G-to-A nucleotide transition in box F 
within the binding site for the cellular transcription factor 
NF-1, it has been reported that NF-1 increases the expres-
sion of early and late JCPyV genes in glial cells, which are 
permissive to viral replication [42, 44, 45].
In conclusion, the present study confirms that this in 
vitro system can be used to grow the CY archetype form 
of JCPyV. This model could be useful for investigating the 
natural history of infection and developing means to pre-
vent transmission and reactivation. It can also be used to 
study the possibility of JCPyV NCCR rearrangement at 
sites of viral persistence, such us the tubular epithelia of 
kidneys and to understand the effect of NCCR rearrange-
ments on early and late gene expression.
It is important to understand the nature of JCPyV infec-
tion in cell types supporting productive viral infection and 
to determine which cell types are involved in the process 
of JCPyV rearrangement. This is the missing piece in the 
pathogenesis puzzle of PML: in fact, the importance of 
NCCR rearrangements in the onset of PML has been dem-
onstrated by the discovery of highly rearranged sequences 
in patients with this condition. However, it is not yet under-
stood where and when these rearrangements occur, or if 
they occur during primary infection or during the period of 
persistence of the virus in the host.
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